The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer

Triple negative breast cancer (TNBC) is an aggressive subtype that accounts for 15-20% of cases, with a higher incidence of relapse/death. Even with adjuvant chemotherapy, the 5 year distant metastasis-free survival rate remains low. A total of 452 tumor registry patients with TNBC and no evidence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Biswas, Tithi, Efird, Jimmy T., Prasad, Shreya, Jindal, Charulata, Walker, Paul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762543/
https://www.ncbi.nlm.nih.gov/pubmed/29348858
http://dx.doi.org/10.18632/oncotarget.22521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762543/
https://www.ncbi.nlm.nih.gov/pubmed/29348858
http://dx.doi.org/10.18632/oncotarget.22521

Ejemplares similares